Skip to Content
Investing Specialists

10 Health-Care Stocks to Consider Buying Now

Our Ultimate Stock-Pickers continue to load up on health-care stocks.

Mentioned: , , , , , , , , ,

By Bradley Meeks | Stock Analyst

Much as we had noted during an early run-through of the holdings of several of our Ultimate Stock-Pickers last month, health care continues to be an area of focus for our top managers. Given that the sector is one of the few areas where our analysts are still finding value, with 19 out of the 49 stocks we currently have rated 5 stars coming from the health-care sector, it didn't come as too much of a surprise. As you may recall from our recent overview of  Vanguard PRIMECAP's (VPMCX) holdings, health-care stocks have been under pressure for much of this year over concerns about the impact that a government-sponsored health-care plan could have on the industry's profitability. The question for investors, though, has been whether or not these near-term issues will derail the long-term positive impact that the aging of the baby boomers is expected to have on the industry. Judging from the recent purchases by our Ultimate Stock-Pickers, the answer appears to be no.

While it would be easy to focus on only the top 10 health-care holdings of our top managers, which currently include 5-star names like  Johnson & Johnson (JNJ),  Pfizer (PFE), and  Merck (MRK), we thought we'd look a little bit deeper into the most recent high-conviction purchases made by our Ultimate Stock-Pickers in the sector. Despite already being the largest health-care holding of our top managers coming into the most recent period, Johnson & Johnson continues to be purchased with conviction, with at least one manager making a new money purchase in the stock. Merck and  Novartis (NVS) are two other top health-care holdings that continue to draw the attention of our Ultimate Stock-Pickers, albeit with slightly less conviction than other purchases in the sector. This leaves us then with seven names that aren't in the top 10 health-care holdings, with almost all of them trading at levels below our Consider Buying price.

The Morningstar Ultimate Stock-Pickers Team does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.